Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH AL 2018 | Increasing AML clinical trial participation rates

Despite major advancements in the understanding of the genetic drivers of acute myeloid leukemia (AML) and the pathophysiology of the disease, standard treatment options for AML patients have not experienced any major changes in the past few decades. Clinicians are often hesitant to send patients into clinical trials if the condition of the patient is unlikely to improve. Here, Gail Roboz, MD, from Weill Medical College of Cornell University, New York City, NY, discusses the potential of newly-approved AML drugs on the market and how these drugs may increase clinical trial participation rates. Clinical trials will provide an in-depth understanding of the effects of incorporating these new drugs into current AML treatment regimens, and on their toxicities. This video was recorded at the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary.